ClinicalTrials.gg
CompletedNCT01357902Updated Sep 20, 2017

Lamotrigine Bioequivalence Study to Compare Dispersible Tables With Compressed Tablets in China

A Phase 1 interventional study of Lamotrigine in Epilepsy, sponsored by GlaxoSmithKline. Completed at 1 site in Hong Kong. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-09-20.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies testing lamotrigine in Epilepsy — 2 open to participants now, 2 under way, none of them phase 3. Lamotrigine · Epilepsy.

Enrollment
31st of 36
24 · median 76
Started
2011
with 2 others
Phase 1
9 of 36
none open now
Registered
23rd of 36
by date
Lead sponsor
19 of 36
GlaxoSmithKline

Among the 36 studies testing lamotrigine in Epilepsy, this one is the 31st largest by enrollment, is one of 3 that started in 2011, is one of 9 in phase 1, and was the 23rd registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 36 studies testing lamotrigine in Epilepsy are open now. Recruiting first, the newest first:

All 2 open studies →

About lamotrigine

Lamotrigine: first FDA approval 1994 (LAMICTAL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 282 Epilepsy studies recruiting now, 112 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing lamotrigine in Epilepsy, or all of them as a file.
02

Study summary

It is an open-label, randomised, single dose, two-sequence cross-over study. Twenty-four eligible, healthy, Chinese male subjects will be enrolled after providing written informed consent. Subjects will be randomised into two treatment groups 1 day prior to the first dosing day and will be assigned to regimen sequences (AB or BA) in a balanced fashion in accordance with the randomisation schedule. Regimen A is five lamotrigine 5 mg chewable/dispersible tablets and Regimen B is one lamotrigine 25 mg standard/compressed tablet.

Subjects will receive their allocated regimen on the morning of Day 1 and will undergo study assessments for 7 days (until Day 8). Subjects will receive their alternate randomised treatment after a washout period of 14-21 days from Day 1. Subjects will undergo a further assessment period of 7 days and will attend a follow-up visit during 8-12 days after the second treatment. The total observation period in this study will be 23\~34 days.

Subjects will arrive at the research unit on the evening before each lamotrigine dosing occasion and will remain in the unit until the 24-h post-dose evaluations have been completed (pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24 h). After this, subjects will return home but must return to the unit for further assessments to be made at 36, 48, 72, 96, 120, 144 and 168 h after dosing Study Endpoints/Assessments A total of 19 serial blood samples (5 mL each) will be collected for the measurement of plasma lamotrigine concentrations at each study assessment. Safety and tolerability assessments (monitoring of adverse events and serious adverse events, routine laboratory determinations, vital sign measurements and 12-lead electrocardiogram) will be conducted throughout the study.

03

Conditions studied

  • Epilepsy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. According to medical history and clinical examination, healthy and non-smoking male subjects
  2. Between 18 and 45 years of age, inclusive.
  3. Body weight >=50 kg and 19-24 kg/m2, inclusive.
  4. Male subjects with female partners of must agree to use one of the following methods after the first dose of study treatment and until the follow up visit:

    • Condom plus partner use of a highly effective contraceptive such as occlusive cap (diaphragm or cervical/vault cap) plus spermicidal agent (foam/gel/film/cream/suppository), oral contraceptive, injectable progesterone, implant of etonogestrel or levonorgestrel, estrogenic vaginal ring, percutaneous contraceptive patches, or intrauterine device. OR,
    • Abstinence, defined as sexual inactivity consistent with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
  5. Good compliance with research policies, procedures and restrictions.
  6. Can read and understand the . Informed consent should be obtained prior to admission to the study.
  7. No abnormality revealed by the laboratory tests, or any slight abnormality judged by the investigator to have no clinical significance.
  8. (AST), ALT, alkaline phosphatase and =\<1.5 x (ULN).
  9. Normal systolic (90-140 mmHg) and diastolic (\<90 mmHg) blood pressure at screening, and normal pulse (supine).
  10. A normal 12-lead at pre-study screening.
  11. Single or average duration corrected for heart rate by Bazett's formula (QTcB) or by Fridericia's formula (QTcF) \<450 msec; or QTc \<480 msec in subjects with bundle branch block.
  12. Liver serum virological and tests are negative

Exclusion criteria

Exclusion Criteria:

  1. Any abnormality identified on the screening history and physical or laboratory examination significant cardiovascular, neurological, psychiatric, haematological or renal abnormalities.
  2. Definite or suspected personal history or family history of adverse reactions or to the study drug or to drugs with a similar chemical structure.
  3. Participation in a clinical trial within the 30 days before the start of the study.
  4. The subject has received prescribed medication or over-the-counter (OTC) medicine including herbal medicines within 14 days before the first dosing day. The use of lubricant with spermicide or barrier devices and other contraceptives is permitted.
  5. History of any clinically significant illness within 4 weeks before the study.
  6. History of any clinically significant physical or organic abnormalities.
  7. Abnormalities of 12-lead which the investigators think increase the risk of participation in the study.
  8. History of liver dysfunction such as jaundice, or surface antigen (HBsAg) or antibody (HCAb) positive regardless of level or ALT greater than or equal to 2-times . Subjects with Gilbert's syndrome will be excluded from the study.
  9. Positive pre-study screening result for hepatitis B antigen, hepatitis C antibodies or -1 or HIV-2 antibody.
  10. Subject whose HLA-B*1502 is positive will be exclude from the study.
  11. Abuse of alcohol, defined as an average weekly intake of greater than 21 units or an average daily intake of greater than three units. One unit is equivalent to half a pint (\~ 240 mL) of beer, one (25 mL) measure of spirits or one glass (125 mL) of wine.
  12. Positive pre-study drug/alcohol screen.
  13. History of obvious active haematological disorder or significant blood loss in the past 3 months.
  14. Subject donated blood within a 56-day period or donated plasma within 1 week prior the study.
  15. Subject is mentally or legally incapacitated.
  16. Any other reason at the Investigators' discretion
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Lamictal

    Chinese healthy male subjects were randomized to receive single dose of either 5 mg lamotrigine dispersible/chewable tablets or 25mg compressed/standard tablets.

    Drug: Lamotrigine

Interventions

  • Lamotrigine is a selective inhibitor of a voltage-sensitive sodium channel, is an anti-epileptic drug of the phenyltriazine class.

06

What researchers measure

Primary outcomes

  1. AUC(0-infinity)

    Time frame: taken pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144 and 168 h after each dosing

  2. AUC(0-t)

    Time frame: taken pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144 and 168 h after each dosing

  3. Cmax

    Time frame: taken pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144 and 168 h after each dosing

Secondary outcomes

  1. tmax

    Time frame: taken pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144 and 168 h after each dosing

  2. terminal phase half-life

    Time frame: taken pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144 and 168 h after each dosing

  3. 12-lead electrocardiogram (ECG), vital signs, nursing observations, spontaneous adverse experience reporting and laboratory safety data

    Time frame: at Screening, Day 0, Day1-8, Day15-22 and follow up 7-14 days after second dosing

07

Study locations

1 site
  • GSK Investigational Site
    Shatin, New Territories, Hong Kong
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2011 to primary completion in May 2011, 1 month.

Of 34 industry-sponsored phase 1 interventional studies under Epilepsy, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 10. This study's 1 month is below that.

Counting every sponsor, half of 55 studies reached it within 8 months; a quarter within 3 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2011
First posted
May 23, 2011
StartActual
Apr 18, 2011
Primary completionActual
May 23, 2011
CompletionActual
May 23, 2011
Last update
Sep 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01357902
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 23, 2011
Start date
Apr 18, 2011
Primary completion
May 23, 2011
Completion
May 23, 2011
Last update
Sep 20, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lamotrigine

Start the discussion